Trump Media & Tech Gr Bolsa (NASDAQ: DJT)

Trump Media & Tech Gr (NASDAQ:DJT) Bolsa

Trump Media & Technology

Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.

Core & Main, Inc.

Equities

News

Pre-Market Outlook

Markets

Trading Ideas

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: CNM, KBH, GME, DJT y WOR.

5 acciones en el foco este martes:CNM, KBH, GME, DJT y WOR

5 acciones en el foco este martes: CNM, KBH, GME, DJT y WOR

Usa,President,Donald,Trump,On,Smartphone,And,Stock,Image,In

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Movers

Tech

$BTC

COIN

HOOD

MSTR

TSLA

Las acciones de las “MAGA Seven” fueron duramente golpeadas en el desplome del mercado del lunes, ya que las expectativas de progreso en las criptomonedas disminuyeron, junto con la pérdida de los ganadores de Trump.

Caída de las &#34;MAGA Seven&#34;: ¿Qué está pasando en el mercado?

Trump Media & Technology Group Corp. - Common Stock

Trump Media & Technology Group Corp

DAIICHI JITSUGYO CO LTD by Daiichi Jitsugyo Co Ltd.

Daiichi Jitsugyo Co Ltd

ETF Opportunities Trust T-REX 2X Long DJT Daily Target ETF

Trump Media & Technology Group Corp. - Warrants

<h3>Gainers</h3>
<ul>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares moved upwards by 39.5% to $1.02 during Wednesday's after-market session. The company's market cap stands at $26.4 million. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares rose 18.49% to $0.38. The company's market cap stands at $6.4 million. </li>
<li>Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) shares moved upwards by 11.41% to $0.25. The company's market cap stands at $4.2 million. </li>
<li>Trump Media &amp; Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares rose 6.76% to $21.64. The market value of their outstanding shares is at $4.7 billion. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock rose 6.13% to $2.25. The company's market cap stands at $3.4 million. </li>
<li>Star Fashion Culture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) stock moved upwards by 4.99% to $0.96. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock fell 25.2% to $3.33 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock decreased by 19.22% to $0.41. The company's market cap stands at $10.8 million. </li>
<li>Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) shares declined by 8.81% to $11.5. The company's market cap stands at $1.6 billion. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) stock decreased by 8.32% to $0.52. The market value of their outstanding shares is at $9.0 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares decreased by 5.45% to $0.47. The company's market cap stands at $6.7 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock decreased by 5.01% to $0.15. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

ANTE

BAOS

CMLS

DRCT

NXPL

STBX

STFS

TNMG

TRIP

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares increased by 82.0% to $0.62 during Wednesday's after-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock rose 16.98% to $0.31. The market value of their outstanding shares is at $1.6 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 16.06% to $3.83. The company's market cap stands at $7.3 million. </li>
<li>Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) stock rose 13.22% to $1.37. The market value of their outstanding shares is at $364.5 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock rose 11.21% to $0.33. The market value of their outstanding shares is at $9.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares moved upwards by 8.8% to $2.72. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 46.2% to $4.8 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock decreased by 19.3% to $4.1. The company's market cap stands at $2.2 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock declined by 18.19% to $1.35. The company's market cap stands at $122.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock fell 17.6% to $0.01. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) shares decreased by 17.17% to $11.68. The company's market cap stands at $1.0 billion. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) stock decreased by 11.05% to $1.77. The company's market cap stands at $43.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTV

AUTL

DWTX

LGMK

LUCD

NDRA

NXTC

PCSA

RSLS

SXTP

VERO

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 7.9% to $0.47 during Wednesday's after-market session. The market value of their outstanding shares is at $6.0 million. </li>
<li>AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) shares moved upwards by 7.01% to $57.98. The company's market cap stands at $2.0 billion. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares rose 6.18% to $0.24. The market value of their outstanding shares is at $7.0 million. </li>
<li>Toppoint Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) shares rose 5.98% to $1.24. The market value of their outstanding shares is at $21.7 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock moved upwards by 5.8% to $0.39. The company's market cap stands at $7.0 million. </li>
<li>Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) stock moved upwards by 5.11% to $5.75. The market value of their outstanding shares is at $120.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares fell 11.7% to $1.13 during Wednesday's after-market session. The company's market cap stands at $2.3 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock declined by 9.65% to $0.02. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock decreased by 8.29% to $3.2. The company's market cap stands at $2.1 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) stock declined by 7.49% to $2.1. The company's market cap stands at $4.5 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares declined by 7.07% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) shares declined by 6.98% to $1.6. The market value of their outstanding shares is at $20.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICON

ILAG

IPDN

ONEG

RYDE

SHIP

SUNE

TOPP

UGRO

VSTE

ZCAR

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>BeLive Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIV#NASDAQ">BLIV</a>) stock moved upwards by 27.5% to $7.74 during Wednesday's after-market session. The company's market cap stands at $76.6 million. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares rose 16.78% to $0.73. The market value of their outstanding shares is at $16.1 million. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) stock increased by 9.56% to $5.5. The market value of their outstanding shares is at $9.7 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock moved upwards by 6.7% to $0.64. The company's market cap stands at $7.3 million. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 6.69% to $2.55. The market value of their outstanding shares is at $6.7 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares increased by 5.76% to $0.22. The company's market cap stands at $5.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) shares declined by 13.2% to $3.7 during Wednesday's after-market session. The company's market cap stands at $52.8 million. </li>
<li>Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares declined by 11.01% to $6.43. The company's market cap stands at $21.4 billion. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares fell 10.44% to $1.03. The company's market cap stands at $28.2 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 9.81% to $2.3. The market value of their outstanding shares is at $1.2 million. </li>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) shares decreased by 9.43% to $3.16. The market value of their outstanding shares is at $287.4 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock fell 8.09% to $0.34. The market value of their outstanding shares is at $47.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASYS

BLIV

ERIC

GREE

HTCR

INUV

IVDA

NTRP

RMNI

SVRE

12 Information Technology Stocks Moving In Wednesday's After-Market Session

General

LMND

Lemonade Says Identifies Technical Issue In Car Insurance Quote Flow; Says Technical Issue In Car Insurance Quote Flow Led To Exposure Of Some Data Received By Api Call To Third Party Data Provider; Says To Notify About 190,000 Individuals Affected By Data Exposure; Says Determines Data Incident Is Not Material- SEC filing

AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#NASDAQ">CSCI</a>) reported quarterly losses of $(2.15) per share. This is a 152.94 percent decrease over losses of $(0.85) per share from the same period last year. The company reported $3.30 million in sales this quarter. This is a 175.00 percent increase over sales of $1.20 million the same period last year.

Earnings

CSCI

AEterna Zentaris Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

Semiconductor stocks such as Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), NVIDIA inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are trading higher Wednesday after President Donald Trump announced a 90-day pause on new tariffs for countries that have not retaliated against <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">U.S. trade measures. </a>
What To Know: The broader tech sector rallied in sync, with AMD, Microsoft, Apple, Meta and Amazon all moving higher as the market digested the policy shift. Trump's new approach — which singles out China with a steep 125% tariff while easing up on U.S. allies—was seen as a targeted realignment rather than an across-the-board escalation, giving investors more clarity around future trade impacts.
Treasury Secretary Scott Bessent emphasized that the new 10% reciprocal tariffs for allied countries would act as a temporary floor, adding a degree of near-term certainty for markets. He framed the policy as a correction to long-standing imbalances, calling China's trade position "an own goal." The move marks a sharp turn from recent blanket tariff threats and was interpreted by Wall Street as a bullish development for U.S.-based chipmakers with broad global exposure.
Price Actions: NVIDIA shares closed Wednesday up 18.72% at $114.33, Broadcom shares jumped 18.66% to $185.15 and Arm Holdings shares were up 24.20% to $106.59, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next: •<a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty"> Wall Street Roars As Trump Pauses Tariffs For Non-Retaliator, Hikes China Duties To 125%</a>
Photo: Shutterstock.

AVGO

NVDA

Chip Stocks Surge As Trump Pauses Tariffs For US Allies, Targets China With 125% Duties

Across the recent three months, 7 analysts have shared their insights on East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated East West Bancorp and provided 12-month price targets. The average target is $106.86, accompanied by a high estimate of $120.00 and a low estimate of $90.00. Highlighting a 9.88% decrease, the current average has fallen from the previous average price target of $118.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232474_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive East West Bancorp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $105.00&#x7C;$120.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $90.00&#x7C;$118.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $118.00&#x7C;$127.00 &#x7C; 
&#x7C;Matthew Clark &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $97.00&#x7C;$100.00 &#x7C; 
&#x7C;Gary Tenner &#x7C;DA Davidson &#x7C;Lowers &#x7C;Buy &#x7C; $118.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$125.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to East West Bancorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of East West Bancorp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for East West Bancorp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of East West Bancorp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EWBC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on East West Bancorp analyst ratings.</a>
<h2>About East West Bancorp</h2>
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
<h3>Understanding the Numbers: East West Bancorp's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: East West Bancorp's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: East West Bancorp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 44.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): East West Bancorp's ROE excels beyond industry benchmarks, reaching 3.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): East West Bancorp's ROA excels beyond industry benchmarks, reaching 0.39%. This signifies efficient management of assets and strong financial health.
Debt Management: East West Bancorp's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.47, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

EWBC

Deep Dive Into East West Bancorp Stock: Analyst Perspectives (7 Ratings)

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.6, a high estimate of $50.00, and a low estimate of $36.00. This current average has decreased by 0.33% from the previous average price target of $45.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232461_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Collegium Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $46.00&#x7C;$46.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$37.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Announces &#x7C;Buy &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Collegium Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Collegium Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Collegium Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Collegium Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COLL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Collegium Pharmaceutical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Collegium Pharmaceutical Better</h2>
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
<h3>A Deep Dive into Collegium Pharmaceutical's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Collegium Pharmaceutical's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 21.51%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Collegium Pharmaceutical's net margin excels beyond industry benchmarks, reaching 6.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Collegium Pharmaceutical's ROE stands out, surpassing industry averages. With an impressive ROE of 5.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.76%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.75, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COLL

What Analysts Are Saying About Collegium Pharmaceutical Stock

Ratings for UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $129.0, a high estimate of $146.00, and a low estimate of $105.00. A 5.03% drop is evident in the current average compared to the previous average price target of $135.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232450_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of UMB Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $105.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$139.00 &#x7C; 
&#x7C;Brian Wilczynski &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $146.00&#x7C;$156.00 &#x7C; 
&#x7C;Benjamin Gerlinger &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $127.00&#x7C;$130.00 &#x7C; 
&#x7C;Jon Arfstrom &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $128.00&#x7C;$128.00 &#x7C; 
&#x7C;Nathan Race &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $143.00&#x7C;$142.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to UMB Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UMB Financial's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UMB Financial analyst ratings.</a>
<h2>Discovering UMB Financial: A Closer Look</h2>
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
<h3>Understanding the Numbers: UMB Financial's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: UMB Financial's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 30.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): UMB Financial's ROE excels beyond industry benchmarks, reaching 3.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): UMB Financial's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

Forecasting The Future: 6 Analyst Projections For UMB Financial

Throughout the last three months, 10 analysts have evaluated DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.1, a high estimate of $112.00, and a low estimate of $74.00. Highlighting a 5.81% decrease, the current average has fallen from the previous average price target of $99.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232443_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of DuPont de Nemours's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $81.00&#x7C;$105.00 &#x7C; 
&#x7C;Patrick Cunningham &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $74.00&#x7C;$95.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $76.00&#x7C;$101.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $103.00&#x7C;$102.00 &#x7C; 
&#x7C;Patrick Cunningham &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $95.00&#x7C;$88.00 &#x7C; 
&#x7C;John McNulty &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $112.00&#x7C;$105.00 &#x7C; 
&#x7C;Duffy Fischer &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $89.00&#x7C;$85.00 &#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $105.00&#x7C;$107.00 &#x7C; 
&#x7C;John McNulty &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $105.00&#x7C;$107.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $101.00&#x7C;$104.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DuPont de Nemours. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DuPont de Nemours compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DuPont de Nemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of DuPont de Nemours's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DuPont de Nemours analyst ratings.</a>
<h2>Discovering DuPont de Nemours: A Closer Look</h2>
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025.
<h3>Understanding the Numbers: DuPont de Nemours's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: DuPont de Nemours's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 6.69%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3.82%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): DuPont de Nemours's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.5%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): DuPont de Nemours's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.32%, the company may face hurdles in achieving optimal financial performance.
Debt Management: DuPont de Nemours's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: DuPont de Nemours In The Eyes Of 10 Experts

Analysts' ratings for Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.4, a high estimate of $57.00, and a low estimate of $40.00. Staying constant with the previous average price target, the current average remains unchanged. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232426_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Bank OZK's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jared Shaw &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $40.00&#x7C;$48.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $54.00&#x7C;$58.00 &#x7C; 
&#x7C;Matt Olney &#x7C;Stephens &amp; Co. &#x7C;Raises &#x7C;Equal-Weight &#x7C; $57.00&#x7C;$53.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $48.00&#x7C;$40.00 &#x7C; 
&#x7C;Matt Olney &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $53.00&#x7C;$53.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank OZK. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bank OZK compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bank OZK's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bank OZK's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OZK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bank OZK analyst ratings.</a>
<h2>Discovering Bank OZK: A Closer Look</h2>
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit, and individual retirement accounts to loan services like real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking, and other related services.
<h3>Bank OZK: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Bank OZK showcased positive performance, achieving a revenue growth rate of 1.17% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bank OZK's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 43.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.35%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bank OZK's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Bank OZK adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Bank OZK's Future

In the current market session, Baker Hughes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) share price is at $38.75, after a 10.71% increase. Moreover, over the past month, the stock fell by 8.78%, but in the past year, spiked by 14.00%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744232417_0_0.png" alt="Past Year Chart" />

<h3>A Look at Baker Hughes P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 16.1 in the Energy Equipment &amp; Services industry, Baker Hughes Inc. has a lower P/E ratio of 11.74. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744232418_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Baker Hughes

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Freshworks, presenting an average target of $21.07, a high estimate of $25.00, and a low estimate of $13.00. Observing a 7.39% increase, the current average has risen from the previous average price target of $19.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232417_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Freshworks among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Schwartz &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $19.00&#x7C;$24.00 &#x7C; 
&#x7C;Brent Thill &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;Scott Berg &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $25.00&#x7C;$25.00 &#x7C; 
&#x7C;Nick Altmann &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $19.00&#x7C;$17.00 &#x7C; 
&#x7C;Brett Knoblauch &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Overweight &#x7C; $22.00&#x7C;$18.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $23.00&#x7C;$19.00 &#x7C; 
&#x7C;Brian Schwartz &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $24.00&#x7C;$22.00 &#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $20.00&#x7C;$14.00 &#x7C; 
&#x7C;Scott Berg &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $25.00&#x7C;$20.00 &#x7C; 
&#x7C;Brent Bracelin &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $24.00&#x7C;$20.00 &#x7C; 
&#x7C;Michael Berg &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Brian Schwartz &#x7C;Oppenheimer &#x7C;Announces &#x7C;Outperform &#x7C; $22.00&#x7C;- &#x7C; 
&#x7C;Scott Berg &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Elizabeth Porter &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $19.00&#x7C;$18.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Freshworks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Freshworks compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Freshworks's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Freshworks's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FRSH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Freshworks analyst ratings.</a>
<h2>Delving into Freshworks's Background</h2>
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
<h3>Financial Insights: Freshworks</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Freshworks displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 21.52%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Freshworks's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Freshworks's ROE stands out, surpassing industry averages. With an impressive ROE of -1.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Freshworks's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Freshworks's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FRSH

Beyond The Numbers: 14 Analysts Discuss Freshworks Stock

WIIM

US Steel shares are trading lower after President Trump indicated he doesn't want to see the company go to Japan.

Following President Donald Trump&#8216;s <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44721342/bet-against-temporary-tariff-pause-citigroup-c-stock">announced tariff delay</a> on Wednesday, the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) closed up 8.50%, one of the best days in the index&#8217;s history. But what components of the index performed the best?
The following small-cap stocks in the Russell 2000 performed among the best on Wednesday, according to <a href="http://benzinga.com/pro">Benzinga Pro</a>:
<ul>
<li>Humacyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>), up 33.04% from $1.15 to $1.53.</li>
<li>Forward Air Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>), up 31.90% from $10.50 to $13.85.</li>
<li>FormFactor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>), up 28.39% from $23.18 to $29.76.</li>
<li>SiTime Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>), up 28.35% from $116.79 to $149.90.</li>
<li>Lovesac Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>), up 27.75% from $12.47 to $15.93.</li>
<li>IONQ Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) up 23.92% from $21.28 to $26.37.</li>
<li>Wolverine World Wide Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>), up 22.44% from $10.07 to $12.33.</li>
<li>FTAI Aviation Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>), up 21.07% from $89.99 to $108.95.</li>
</ul>
Semiconductor components, as reflected by the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), are among the other top performers in the index on Wednesday. Trump's tariffs raised concerns about disruptions to a global supply chain spanning the Americas and Asia.
Only around 2.5% of companies in the index closed the day in the red, and around a third closed up over 10%.
Why it Matters: Trump&#8217;s tariff plan, a hallmark of his successful 2024 presidential campaign, sparked widespread fear on Wall Street. Economists generally view tariffs as stagflationary, causing both a cessation of economic growth and an increase in inflation.
From Trump&#8217;s election on Nov. 5, 2024, to April 8, the Russell 2000 index fell over 26%, putting it in bear market territory. The tariffs presumably were feared to hurt small-cap stocks more than large-cap counterparts, as the S&amp;P 500 and NASDAQ indexes saw comparatively smaller declines.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44721874/trumps-tariff-pause-saves-market-from-edge-of-the-cliff-dan-ives-says-biggest-wild-card-still-remains">Trump&#8217;s Tariff Pause Saves Market From &#8216;Edge Of The Cliff,&#8217; Dan Ives Says &#8216;Biggest Wild Card&#8217; Still Remains</a></li>
</ul>
Photo: Shutterstock

Government

Broad U.S. Equity ETFs

ETFs

FORM

FTAI

FWRD

HUMA

IONQ

LOVE

SITM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000

Trump Media & Technology shares are trading higher after markets rebounded following Trump's tariff pause announcement.

BITF

RIOT

Riot Platforms Reports 16.3% Stake In Bitfarms As Of April 7, 2025 Vs Prior Stake Of 19.9% As Of Sept 23, 2024

Guidance

Constellation Brands Outlook EPS Growth For Fiscal 2027 Mid-Single Digit To Low-Double Digit; EPS Growth For Fiscal 2028 Low-Single Digit To Mid-Single Digit

<a href="https://www.youtube.com/watch?v=qr9AeMFXzpY">https://www.youtube.com/watch?v=qr9AeMFXzpY</a>
&nbsp;

Macro Economic Events

Politics

Global

Economics

President Trump Says Think We Will End Up Making Very Good Deal With China

Management

Press Releases

Former Congressman George Holding Joins Trump Media Board

Truth Social Enhances Groups Feature

Voting Begins for Trump Media Annual Meeting

Trump Media Announces Release of Truth+ Streaming on Roku

GrabAGun Nominates Donald Trump Jr. and Post-Closing Board of Directors and Advances Plans for Upcoming Public Listing

Trump Media Announces Intention to Partner with Crypto.com to Launch ETFs

IPOs

Trump Media to Debut on New York Stock Exchange Texas

authID Announces Pricing of Approximately $8,150,000 Million Registered Direct Offering

Trump Media Issues Statement on Filing of Form S-3

Trump Media TV Streaming Apps Now Available in Canada and Mexico

AUID

CLBR

DOMH

DWAC

PSQH

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Comments

Trump Media & Tech Gr

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL